Market Place
Sourcing Support
Sensorion Reports Data from Audiogene Phase 1/2 Gene Therapy Trial
18 Dec 2024 //
BUSINESSWIRE
Sensorion to Present at 43rd J.P. Morgan Healthcare Conference
02 Dec 2024 //
BUSINESSWIRE
Sensorion Announces Webconference For Retail Shareholders
26 Sep 2024 //
BUSINESSWIRE
Sensorion Reports New Results At World Congress Of Audiology
23 Sep 2024 //
BUSINESSWIRE
Sensorion Announces the Availability of its Half Year 2024 Report
23 Sep 2024 //
BUSINESSWIRE
Sensorion Announces New Positive Clinical Data At Congress
20 Sep 2024 //
BUSINESSWIRE
Sensorion Reports 2024 First Half Results and Highlights Recent Updates
18 Sep 2024 //
BUSINESSWIRE
Sensorion To Participate In 59th Annual Inner Ear Biology Workshop
12 Sep 2024 //
BUSINESSWIRE
Sensorion To Lead Hearing Loss Symposium At World Congress Of Audiology
02 Sep 2024 //
BUSINESSWIRE
Sensorion Announces its Participation in Stifel`s Biotech Summer Summit
05 Aug 2024 //
BUSINESSWIRE
Sensorion`s DSMB Recommends Continuing SENS-401 Trial For Ototoxicity
22 Jul 2024 //
BUSINESSWIRE
Sensorion Reports New Positive Data From SENS-401 Phase 2a Trial
15 Jul 2024 //
BUSINESSWIRE
Sensorion Announces the Appointment of Laurene Danon as Chief Financial Officer
26 Jun 2024 //
BUSINESSWIRE
Sensorion To Present SENS-401 Results At Cochlear Implants Conference
20 Jun 2024 //
BUSINESSWIRE
Sensorion Publishes AGM Shareholder Resolutions
30 May 2024 //
BUSINESSWIRE
Sensorion Investor Conference Schedule: Participation In June 2024 Events
28 May 2024 //
BUSINESSWIRE
Sensorion Shareholder Meeting Documents For May 29
07 May 2024 //
BUSINESSWIRE
Sensorion Announces a €15 Million Financing
08 Apr 2024 //
BUSINESSWIRE
Sensorion Reports Full-Year 2023 Financial Results and Business Update
14 Mar 2024 //
BUSINESSWIRE
Sensorion Announces the Availability of its Financial Report for 2023
14 Mar 2024 //
BUSINESSWIRE
Sensorion Announces it Has Met Primary Endpoint for SENS-401 Phase 2a Study
11 Mar 2024 //
BUSINESSWIRE
Sensorion`s hearing loss drug reaches target in comeback story
11 Mar 2024 //
FIERCE BIOTECH
Sensorion Will Host a Webcast to Announce its 2023 Annual Financial Results
06 Mar 2024 //
BUSINESSWIRE
Sensorion Announces Participation in Leerink Partners Biopharma Conference
29 Feb 2024 //
BUSINESSWIRE
Sensorion Announces a €50.5 Million Financing
09 Feb 2024 //
BUSINESSWIRE
Sensorion Announces the Completion of Patient Inclusion in Phase 2a of SENS-401
01 Feb 2024 //
BUSINESSWIRE
Sensorion Appoints Dr. Federico Mingozzi as Non-Executive Director
25 Jan 2024 //
BUSINESSWIRE
Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate SENS-501
19 Jan 2024 //
BUSINESSWIRE
Sensorion Announces Partnership With the Institut Pasteur
05 Jan 2024 //
BUSINESSWIRE
Sensorion Publishes Results of Combined General Meeting Resolutions
21 Dec 2023 //
BUSINESSWIRE
Sensorion Provides an Update on NOTOXIS
18 Dec 2023 //
BUSINESSWIRE
Sensorion Appoints CMC Expert Bernd Schmidt as New Chief Technical Officer
12 Dec 2023 //
BUSINESSWIRE
Sensorion Announces Its Attendance at the 42nd Annual J.P. Morgan Healthcare
23 Nov 2023 //
BUSINESSWIRE
Sensorion to Participate in the Jefferies London Healthcare Conference
25 Oct 2023 //
BUSINESSWIRE
Sensorion Announces Availability of Financial Report for the 1st Half of 2023
26 Sep 2023 //
BUSINESSWIRE
Sensorion Announces Webconference on September 25, 2023
21 Sep 2023 //
BUSINESSWIRE
Sensorion Reports 2023 First Half Results
20 Sep 2023 //
BUSINESSWIRE
Sensorion Submits Trial Application for OTOF-GT, Gene Therapy Candidate
19 Jul 2023 //
BUSINESSWIRE
Sensorion Submits Trial Application for Lead Gene Therapy Candidate OTOF-GT
10 Jul 2023 //
BUSINESSWIRE
Sensorion candidate reduces hearing loss in small midphase trial
05 Jul 2023 //
FIERCE BIOTECH
Sensorion Reports Positive Efficacy Data from SENS-401 Phase 2a Clinical Study
05 Jul 2023 //
BUSINESSWIRE
Sensorion unveils promising initial results from trial of SENS-401
19 Jun 2023 //
CLINICAL TRIALS ARENA
Sensorion Publishes Results of Combined Shareholders’ Meeting Resolutions
25 May 2023 //
BUSINESSWIRE
Sensorion Will Present Two Posters At The A (ASGCT) 26th Annual Meeting
10 May 2023 //
BUSINESSWIRE
Sensorion to Host a Symposium during ISIET’s International Symposium Inner Ear
24 Apr 2023 //
BUSINESSWIRE
Sensorion to participate in Chardan’s Annual Genetic Medicines & Cell Therap
18 Apr 2023 //
BUSINESSWIRE
Sensorion Appoints Khalil Barrage as Interim Chairman of the Board
31 Mar 2023 //
BUSINESSWIRE
Sensorion Announces Agenda For R&D Day Showcasing Gene Therapy For Ear Disease
14 Mar 2023 //
BUSINESSWIRE
Sensorion to Participate in the 6th Annual Bioprocessing Summit Europe
07 Mar 2023 //
BUSINESSWIRE
Sensorion Appoints David Lawrence as Chief Financial Officer
27 Feb 2023 //
BUSINESSWIRE
Sensorion Will Present at the Association for Research in Otolaryngology ARO
02 Feb 2023 //
BUSINESSWIRE
Sensorion taps Eveon to deliver gene therapy to inner ear
31 Jan 2023 //
FIERCE PHARMA
Sensorion Will Take Part in a Press Conference Launching UNESCO Week of Sound
05 Jan 2023 //
BUSINESSWIRE
Sensorion Announces First Enrolled in Ph2a Proof of Concept Trial of SENS-401
03 Jan 2023 //
BIOSPACE
Sensorion Announces Its Attendance at the 41st Annual J.P. Morgan Healthcare
04 Dec 2022 //
BUSINESSWIRE
Sensorion Will Attend In-Person the Jefferies London Healthcare Conference
09 Nov 2022 //
BUSINESSWIRE
US FDA grants Rare Paediatric Disease Designation to Sensorion’s OTOF-GT
08 Nov 2022 //
PHARMABIZ
Sensorion nabs rare pediatric designation for gene therapy
07 Nov 2022 //
ENDPTS
Sensorion Announces Approval to Initiate Phase 2a Trial of SENS-401
24 Oct 2022 //
BUSINESSWIRE
